Dr. Horwitz on the Future of CHOP for T-Cell Lymphoma

Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of the CHOP regiment for t-cell lymphoma.

Whether or not CHOP remains a common treatment regiment for t-cell lymphoma depending largely on how combinations that include CHOP do in clinical trials, says Horwitz.

If studies including CHOP do not do well, it could eventually be replaced. However it does offer a high response rate and a high cure rate, so it will probably never entirely be abandoned as a treatment option for t-cell lymphoma.